skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I hold AMGN and see from your recent responses that it's a 5i favorite. The metrics do not appear to justify your support, so I wonder if I am looking at the wrong data. PEG is sky high (over 4); forward P/E is almost 14 ; ROE is only 6.6. The data above is from a premium site which differs from the Yahoo Finance site which shows forward P/E at 13.09 and PEG at 3.3 with ROE at only 7.18. Net margins do look healthy but I cannot tell from 3 sites I checked whether net margin % data is fwd looking or refers to historical.

Although AMGN appears to have been a dividend grower (not a dividend aristocrat that I know of ) , it’s dividend payout is very high at 171%.

Yet there must be something about AMGN that you like a lot.... perhaps something not shown on reported data. Is it AMGN's pipeline? Projected cash flow? I would prefer not to sell my holding until I can understand what it is about AMGN that you like so much. I would appreciate your insight very much (am not looking so much for basic or raw numbers available on popular sites---but I really would appreciate your thoughts, thanks).
Read Answer Asked by Adam on February 21, 2018
Q: 5i,
Im looking into investing into the healthcare sector in the US market. What companies would you recommend for growth?
Read Answer Asked by D on February 20, 2018
Q: ATE is set to release final Phase 2b results of their lead drug ATB-346, in 4weeks. I'm curious if you have any relevant information on the outlook of this drug and the company overall? I understand GUD has funds deployed here. And my main question is if the trial results show less GI tract bleeding (the issue with prolonged doses of Naproxen) and better efficacy results than Aleve then how could the drug or company's valuation be estimated? Sales numbers for Bayer's Aleve that could be extrapolated? thanks
Read Answer Asked by Gordon on February 16, 2018
Q: SNY (not in your database) recently reported a poor quarter and so-so guidance. On the other hand, the P/E is now less than 12x, the dividend is substantial, and the pipeline should be broad enough to protect against single-drug risk. My sense is that it's long-term-investable, but less attractive than other beaten-down pharma blue-chips (say, LLY); your opinion?
Read Answer Asked by John on February 16, 2018
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!